Africa’s path to pharmaceutical independence: breaking free from dependency

For decades, most African nations have relied on imported drugs to meet their populations’ healthcare needs. In this analysis, pharmacist and engineer Dr. Arnaud Kaboré outlines a roadmap for public leaders to achieve pharmaceutical sovereignty by 2045.

Why Africa can no longer afford pharmaceutical dependency

Today, fewer than five African countries operate manufacturing facilities capable of exporting beyond their regional borders. This leaves the continent importing 94% of its medicines at an annual cost exceeding $18 billion—a figure projected to surpass $30 billion by 2030.

Beyond economics, this dependency creates dangerous vulnerabilities. Over 70% of public health facilities in Africa report experiencing critical stockouts at least once per quarter. The human cost is staggering: poorly managed diseases, medication prices tripling during shortages, and public health programs collapsing due to unavailable treatments. The Covid-19 pandemic exposed these flaws, alongside chronic shortages of essential drugs like amoxicillin, insulin, and anesthetics, while cancer treatments and innovative therapies remain inaccessible to most.

Africa’s untapped potential for pharmaceutical independence

Despite these challenges, Africa possesses significant advantages:

• A rapidly expanding market projected to exceed $70 billion by 2030

• Over 5,400 documented medicinal plants, some already integrated into official therapeutic protocols

• Progress in regulatory harmonization through the African Medicines Agency (AMA), now ratified by 27 countries

• Strong political will exemplified by ambitious local production initiatives in countries like Burkina Faso, Rwanda, Egypt, Morocco, Senegal, and South Africa

Building Africa’s pharmaceutical future: a strategic approach

One fundamental error has been attempting to replicate international ‘Big Pharma’ models without establishing local foundations. Industrial development requires more than imported equipment—it demands investment in human capital, technical expertise, and local industrial assets.

Many initiatives have failed because they prioritized immediate production over long-term capacity building. This approach leads to locally produced drugs costing more than imports while maintaining dependence on foreign raw materials, technology, and expertise. True pharmaceutical sovereignty demands rigorous methodology, strategic vision, and sustained commitment.

Success requires focusing on Africa’s inherent strengths: its growing market, medicinal biodiversity, advancing regulatory frameworks, and demonstrated political commitment. Public leaders must develop clear, pragmatic strategies anchored in local needs rather than foreign models. The goal isn’t just pharmaceutical independence—it’s building an industry that serves African healthcare today while positioning the continent as a global supplier tomorrow.

Dr. Arnaud Kaboré

Pharmacist and Health Sector Executive